diquafosol has been researched along with Dry Eye in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (12.05) | 29.6817 |
| 2010's | 54 (65.06) | 24.3611 |
| 2020's | 19 (22.89) | 2.80 |
| Authors | Studies |
|---|---|
| Brunschweiger, A; Müller, CE | 1 |
| Jin, R; Li, L; Li, Y; Yoon, HJ; Yoon, HS; Yoon, KC | 1 |
| Asano, H; Hiraoka, T; Ogami, T; Oshika, T; Yamada, Y | 1 |
| He, W; He, X; Moore, JE; Moutari, S; Palme, C; Pazo, EE; Qin, G; Song, Y; Wu, Y; Xu, L; Yang, L; Yu, S; Zhang, H; Zhang, Q | 1 |
| Akasaki, Y; Fujimoto, K; Fujio, K; Hirosawa, K; Huang, T; Inomata, T; Iwagami, M; Kuwahara, M; Midorikawa-Inomata, A; Miura, M; Murakami, A; Nagao, M; Nakamura, M; Nojiri, S; Okumura, Y; Shimazaki, J; Sung, J | 1 |
| Graue-Hernandez, EO; Kahuam-López, N; Navas, A; Pérez Vázquez, AK; Ramirez-Miranda, A; Serrano-Robles, JG | 1 |
| Hori, Y; Inai, M; Oka, K | 1 |
| Bereiter, DA; Iwata, K; Katagiri, A; Kato, T; Mikuzuki, L; Nakamura, S; Toyofuku, A; Tsubota, K | 2 |
| Cheng, W; Feng, X; Jin, X; Liu, C; Liu, Q; Ming, S; Zhao, D | 1 |
| Du, M; Du, X; Guo, Y; Li, S; Sheng, Y; Wang, X; Yang, Z | 1 |
| Li, Q; Liu, S; Tang, S; Yang, G | 1 |
| Liu, C; Liu, L; Sun, X | 1 |
| Baek, J; Kim, EC; Kim, HS; Kim, MS; Lee, JY; So, HR | 1 |
| Che, H; Chen, J; He, W; He, X; Huang, H; Li, L; Moore, JE; Moutari, S; Pazo, EE; Qi, Y; Qin, G; Wu, Y; Xia, Y; Xu, L; Yang, L; Yu, S; Zhang, Q | 1 |
| Jia, F; Jiang, L; Jin, H; Li, Z; Xu, W; Zhao, X | 1 |
| Gao, D; Lv, X; Song, Y; Xu, Y; Zhang, F | 1 |
| Choi, S; Choi, YJ; Jun, I; Kim, EK; Kim, TI; Lee, GY; Lee, HK; Seo, KY | 1 |
| Appy, L; Chardet, C; Peyrottes, S; Roy, B | 1 |
| Choi, CY; Ji, YW; Kim, HM; Kim, HS; Kim, KP; Kim, MJ; Lee, HK; Oh, JW; Ryu, SY; Seo, KY; Song, JS; Yeo, A | 1 |
| Gum, SI; Jung, JC; Kim, BA; Kim, YH; Lee, GJ; Nguyen, LTH; Park, YJ; Yang, IJ; Yu, S | 1 |
| Endo, KI; Fujisawa, K; Sakamoto, A | 1 |
| Kim, S; Lee, JE; Shin, J | 1 |
| Hanada, K; Kawahara, A; Utsunomiya, T; Yoshida, A | 1 |
| Chung, JL; Kim, BY; Koh, KM; Kwon, YA; Lee, KB; Song, SW | 1 |
| Ahn, BN; Kim, CE; Lee, H; Yang, J | 1 |
| Choi, W; Cui, L; Lee, HS; Li, Y; Yang, JM; Yoon, KC | 1 |
| Choi, W; Kang, YS; Kim, YH; Lee, HS; Yoon, KC; You, IC | 1 |
| Chen, Y; Xia, S; Zhao, X | 1 |
| Fukagawa, K; Iwasaki, M; Okano, T; Saga, M; Sakata, M; Seika, D; Shimazaki, J | 1 |
| Fukui, M; Kamoi, M; Kozuki, N; Mori, T; Mukai, S; Ogawa, Y; Okamoto, S; Saijo-Ban, Y; Tsubota, K; Uchino, M; Yamane, M | 1 |
| Dogru, M; Higa, K; Ikeda, K; Kawashima, M; Kojima, T; Shimazaki, J; Shimizu, T; Simsek, C; Tsubota, K | 1 |
| Kaido, M; Kawashima, M; Shigeno, Y; Tsubota, K; Yamada, Y | 1 |
| Kang, S; Kim, CE; Kim, K; Kleinman, HK; Ousler, GW; Sosne, G; Yang, J | 1 |
| Kwon, JW; Mun, Y; Oh, JY | 1 |
| Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A | 1 |
| Kang, DH; Kang, SS; Kim, JY; Moon, SH; Park, JH; Tchah, H; Um, HJ | 1 |
| Georgiev, GA; Yokoi, N | 1 |
| Watanabe, H | 1 |
| Hori, Y | 1 |
| Kim, HJ; Nam, K; Yoo, A | 1 |
| Choi, CY; Chung, TY; Kim, EC; Kim, HK; Kim, HS; Kim, JY; Kim, MK; Kim, TI; Lee, DH; Lee, HK; Park, CH; Song, JS; Yoon, KC | 2 |
| Arita, R; Fukuoka, S | 1 |
| Choi, YH; Kim, DH; Kim, MK; Kim, Y; Paik, HJ | 1 |
| Dogru, M; Iseda, H; Shimazaki, J; Shimazaki-Den, S | 1 |
| Ikeda, C; Koh, S; Maeda, N; Nishida, K; Takai, Y; Watanabe, H | 1 |
| Fukumoto, T; Ichihashi, Y; Ide, T; Toda, I; Tsubota, K | 1 |
| Amano, S; Maruyama, Y; Masuda, A; Minami, K; Miyata, K; Mori, Y; Nejima, R | 1 |
| Hwang, HS; Kim, EC; Lee, WS; Sung, YM | 1 |
| Nishijima, T; Ohashi, Y; Shimazaki, J; Takamura, E; Watanabe, H; Yamaguchi, M; Yokoi, N | 1 |
| Igarashi, A; Kamiya, K; Kobashi, H; Miyake, T; Shimizu, K | 1 |
| Chen, X; Chua, WH; Chuan, JC; Gong, L; Gu, Y; Ma, Z; Shao, Y; Sun, X; Tang, L; Tong, L; Wang, Q; Xu, X; Yao, K; Yuan, H | 1 |
| Fukui, M; Kamoi, M; Kawakita, T; Mukai, S; Ogawa, Y; Saijo-Ban, Y; Simmura, S; Tsubota, K; Yaguchi, S; Yamane, M | 1 |
| Koh, S; Maeda, N; Nagahara, Y; Nishida, K; Watanabe, H | 1 |
| Keating, GM | 1 |
| Choi, W; Kim, N; Yang, JM; Yoon, KC | 1 |
| Kato, H; Kinoshita, S; Komuro, A; Sonomura, Y; Yokoi, N | 1 |
| Akune, Y; Shigeyasu, C; Tsubota, K; Yamada, M | 1 |
| Chung, JK; Lee, SJ; Park, DH; Seo, DR | 1 |
| Jin, SW; Min, JS | 1 |
| Akiyama-Fukuda, R; Usui, T; Yamagami, S; Yoshida, T | 1 |
| Baek, J; Chung, SK; Doh, SH | 1 |
| Akune, Y; Fukui, M; Shigeyasu, C; Yamada, M | 1 |
| Koh, S; Mano, H; Nagahara, Y; Nagano, T; Nishida, K; Oshita, Y; Watanabe, H | 1 |
| Hyon, JY; Jeon, HS | 1 |
| Akune, Y; Shigeyasu, C; Yamada, M | 1 |
| Hiratsuka, Y; Kawashima, M; Shigeyasu, C; Suwaki, K; Tsubota, K; Uchino, M; Yamada, M; Yokoi, N | 1 |
| Choi, S; Kim, EK; Kim, SM; Kim, TI; Lee, H; Seo, KY | 1 |
| Matsumoto, Y; Ohashi, Y; Tsubota, K; Watanabe, H | 1 |
| Imanaka, T; Nakamura, M; Sakamoto, A | 1 |
| Igarashi, A; Ishii, R; Kamiya, K; Kobashi, H; Nakanishi, M; Sato, N; Shimizu, K | 1 |
| Ohashi, Y; Takamura, E; Tsubota, K; Watanabe, H | 1 |
| Bremond-Gignac, D; Gicquel, JJ | 1 |
| Fujihara, T; Murakami, T; Nagano, T; Nakamura, M; Nakata, K | 1 |
| Cooper, M; Garden, JC; Kellerman, DJ; Mundasad, M; Sylvester, RN; Yerxa, BR | 1 |
| Kellerman, DJ; Nichols, KK; Yerxa, B | 1 |
| Fischbarg, J | 1 |
| Bokosky, JE; Davitt, WF; Kellerman, DJ; LaVange, LM; Mills-Wilson, MC; Nichols, KK; Schaberg, AE; Tauber, J; Yerxa, BR | 1 |
| Pintor, J | 1 |
| Fujihara, T; Fujita, H; Murakami, T; Nakamura, M; Nakata, K | 1 |
| Allgood, VE; Evans, RM; Gorden, JC; Mundasad, MV; Novack, GD; Yerxa, BR | 1 |
14 review(s) available for diquafosol and Dry Eye
| Article | Year |
|---|---|
P2 receptors activated by uracil nucleotides--an update.
Topics: Bone and Bones; Cystic Fibrosis; Dry Eye Syndromes; Humans; Hypersensitivity; Inflammation; Lung Diseases, Obstructive; Neoplasms; Nucleic Acid Conformation; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Uracil Nucleotides | 2006 |
Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials.
Topics: Cataract Extraction; Dry Eye Syndromes; Humans; Hyaluronic Acid; Lubricant Eye Drops; Ophthalmic Solutions; Polyphosphates; Randomized Controlled Trials as Topic; Tears; Uracil Nucleotides | 2023 |
Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.
Topics: Dry Eye Syndromes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Tears | 2023 |
Synthetic Strategies for Dinucleotides Synthesis.
Topics: Deoxycytosine Nucleotides; Dinucleoside Phosphates; Dry Eye Syndromes; Green Chemistry Technology; Humans; Ophthalmic Solutions; Phosphorylation; Polyphosphates; Purinergic P2Y Receptor Agonists; Receptors, Purinergic; Uracil Nucleotides; Uridine | 2019 |
Comparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: A meta-analysis of randomized controlled trials.
Topics: Cataract Extraction; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Treatment Outcome; Uracil Nucleotides | 2017 |
Tear Film-Oriented Diagnosis and Tear Film-Oriented Therapy for Dry Eye Based on Tear Film Dynamics.
Topics: Alanine; Antioxidants; Dry Eye Syndromes; Humans; Japan; Mucins; Ophthalmic Solutions; Polyphosphates; Quinolones; Tears; Uracil Nucleotides; Wettability | 2018 |
Medical Treatment for Dry Eye in Japan.
Topics: Alanine; Dry Eye Syndromes; Humans; Japan; Lubricant Eye Drops; Polyphosphates; Quinolones; Tears; Uracil Nucleotides | 2018 |
Secreted Mucins on the Ocular Surface.
Topics: Alanine; Conjunctiva; Dry Eye Syndromes; Goblet Cells; Humans; Mucin 5AC; Ophthalmic Solutions; Polyphosphates; Quinolones; Uracil Nucleotides | 2018 |
Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials.
Topics: Cataract Extraction; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Polyphosphates; Randomized Controlled Trials as Topic; Tears; Uracil Nucleotides | 2019 |
Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
Topics: Animals; Dry Eye Syndromes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Time Factors; Uracil Nucleotides | 2015 |
Diquafosol ophthalmic solution for dry eye treatment.
Topics: Dry Eye Syndromes; Humans; Mucins; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Tears; Treatment Outcome; Uracil Nucleotides | 2012 |
Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998.
Topics: Administration, Inhalation; Clinical Trials as Topic; Dry Eye Syndromes; Expectorants; Humans; Ophthalmic Solutions; Polyphosphates; Respiratory Tract Diseases; Uracil Nucleotides | 2003 |
Diquafosol tetrasodium: a novel dry eye therapy.
Topics: Biological Availability; Clinical Trials as Topic; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Treatment Outcome; Uracil Nucleotides | 2004 |
Diquafosol tetrasodium. Inspire/Allergan/Santen.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dry Eye Syndromes; Half-Life; Humans; Ophthalmic Solutions; Polyphosphates; Structure-Activity Relationship; Treatment Outcome; Uracil Nucleotides | 2003 |
29 trial(s) available for diquafosol and Dry Eye
| Article | Year |
|---|---|
The Effect of Diquafosol Ophthalmic Solution on Clinical Parameters and Visual Function in Soft Contact Lens-Related Dry Eye.
Topics: Contact Lenses, Hydrophilic; Cornea; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2021 |
Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
Topics: Diabetes Mellitus, Type 2; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Meibomian Glands; Ophthalmic Solutions; Pilot Projects; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2022 |
Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomised controlled trial.
Topics: Cataract; Dry Eye Syndromes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Polyphosphates; Randomized Controlled Trials as Topic; Single-Blind Method; Sodium; Tears; Treatment Outcome; Uracil Nucleotides | 2022 |
Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Topics: Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dry Eye Syndromes; Fluorescein; Humans; Ophthalmic Solutions; Polyphosphates; Tears; Treatment Outcome; Uracil Nucleotides | 2022 |
Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome.
Topics: Dry Eye Syndromes; Humans; Lacerations; Male; Ophthalmic Solutions; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2023 |
A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Prospective Studies | 2023 |
Effects of Preservative-free 3% Diquafosol in Patients with Pre-existing Dry Eye Disease after Cataract Surgery: A Randomized Clinical Trial.
Topics: Aged; Cataract Extraction; Dry Eye Syndromes; Female; Humans; Male; Meibomian Glands; Polyphosphates; Preservatives, Pharmaceutical; Uracil Nucleotides | 2019 |
Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
Topics: Administration, Topical; Conjunctiva; Cornea; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Proteome; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
A randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery.
Topics: Aged; Cataract Extraction; Dry Eye Syndromes; Female; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Postoperative Care; Prospective Studies; Tears; Treatment Outcome; Uracil Nucleotides | 2021 |
Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study.
Topics: Adult; Anterior Eye Segment; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Humans; Male; Ophthalmic Solutions; Polyphosphates; Tears; Tomography, Optical Coherence; Uracil Nucleotides | 2017 |
Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye.
Topics: Cataract; Cataract Extraction; Cell Count; Conjunctiva; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Postoperative Period; Prospective Studies; Treatment Outcome; Uracil Nucleotides | 2018 |
Effectiveness of Combined Tear Film Therapy in Patients with Evaporative Dry Eye with Short Tear Film Breakup Time.
Topics: Acrylic Resins; Adult; Conjunctiva; Cornea; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Hyaluronic Acid; Lipids; Lubricant Eye Drops; Male; Middle Aged; Mucins; Polyphosphates; Prospective Studies; Time Factors; Treatment Outcome; Uracil Nucleotides | 2017 |
A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers.
Topics: Adult; Alanine; Conjunctiva; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Occupational Diseases; Polyphosphates; Prospective Studies; Quality of Life; Quinolones; Sclera; Secretagogues; Surveys and Questionnaires; Treatment Outcome; Uracil Nucleotides | 2017 |
Randomized Controlled Study to Investigate the Effect of Topical Diquafosol Tetrasodium on Corneal Sensitivity in Short Tear Break-Up Time Dry Eye.
Topics: Administration, Topical; Adult; Cornea; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Time Factors; Treatment Outcome; Uracil Nucleotides | 2018 |
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides; Young Adult | 2019 |
Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study.
Topics: Adult; Aged; Dry Eye Syndromes; Female; Humans; Lipid Metabolism; Male; Meibomian Gland Dysfunction; Middle Aged; Polyphosphates; Tears; Uracil Nucleotides; Young Adult | 2019 |
Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
Topics: Administration, Topical; Adult; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Nanotechnology; Polyphosphates; Prospective Studies; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye.
Topics: Adult; Aged; Aged, 80 and over; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Uracil Nucleotides | 2013 |
Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis.
Topics: Adult; Cornea; Drug Therapy, Combination; Dry Eye Syndromes; Female; Humans; Hyaluronic Acid; Keratomileusis, Laser In Situ; Male; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Refraction, Ocular; Surveys and Questionnaires; Tears; Uracil Nucleotides; Viscosupplements; Visual Acuity | 2014 |
Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Topics: Aged; Drug Combinations; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Preservatives, Pharmaceutical; Purinergic P2Y Receptor Agonists; Rose Bengal; Tears; Uracil Nucleotides; Viscosupplements | 2014 |
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.
Topics: Aged; Asian People; China; Dry Eye Syndromes; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Rose Bengal; Singapore; Staining and Labeling; Tears; Treatment Outcome; Uracil Nucleotides; Viscosupplements | 2015 |
Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Lens Implantation, Intraocular; Lissamine Green Dyes; Male; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Staining and Labeling; Surveys and Questionnaires; Tears; Uracil Nucleotides; Viscosupplements; Visual Acuity | 2016 |
The Effect of Topical Diquafosol Tetrasodium 3% on Dry Eye After Cataract Surgery.
Topics: Administration, Topical; Aged; Cataract Extraction; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Postoperative Complications; Retrospective Studies; Surveys and Questionnaires; Tears; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Uracil Nucleotides | 2016 |
Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Topics: Administration, Topical; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Fluorophotometry; Humans; Japan; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Treatment Outcome; Uracil Nucleotides | 2012 |
Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Rose Bengal; Tears; Uracil Nucleotides; Viscosupplements | 2012 |
A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.
Topics: Cornea; Double-Blind Method; Dry Eye Syndromes; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Polyphosphates; Rose Bengal; Treatment Outcome; Uracil Nucleotides; Viscosupplements | 2012 |
Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.
Topics: Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Eye; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Safety; Severity of Illness Index; Single-Blind Method; Time Factors; Uracil Nucleotides | 2002 |
Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Topics: Administration, Topical; Conjunctiva; Contrast Media; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Safety; Staining and Labeling; Tears; Treatment Outcome; Uracil Nucleotides | 2004 |
Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.
Topics: Administration, Topical; Adult; Cohort Studies; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Lacrimal Apparatus; Male; Middle Aged; Mucins; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Safety; Tears; Uracil Nucleotides | 2001 |
40 other study(ies) available for diquafosol and Dry Eye
| Article | Year |
|---|---|
Effects of eye drops containing a mixture of 3% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye.
Topics: Administration, Ophthalmic; alpha-Tocopherol; Animals; Conjunctiva; Cornea; Disease Models, Animal; Drug Combinations; Dry Eye Syndromes; Female; Humans; Mice; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2021 |
Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a systematic review.
Topics: Dry Eye Syndromes; Humans; Lubricant Eye Drops; Meta-Analysis as Topic; Pilocarpine; Polyphosphates; Quinuclidines; Secretagogues; Systematic Reviews as Topic; Thiophenes; Uracil Nucleotides | 2022 |
Diquafosol sodium reduces neuronal activity in trigeminal subnucleus caudalis in a rat model of chronic dry eye disease.
Topics: Animals; Dry Eye Syndromes; Neurons; Ophthalmic Solutions; Pain; Rats; Sodium; Tears; Uracil Nucleotides | 2023 |
Evaluation of effects of 3% diquafosol ophthalmic solution on preocular tear film stability after trabeculectomy.
Topics: Cornea; Dry Eye Syndromes; Glaucoma; Humans; Ophthalmic Solutions; Retrospective Studies; Tears; Trabeculectomy | 2023 |
Analysis of risk factors for dry eye disease and effect of diquafosol sodium ophthalmic solution on the tear film after vitrectomy in patients with type 2 diabetes mellitus: a preliminary study.
Topics: Diabetes Mellitus, Type 2; Dry Eye Syndromes; Glycated Hemoglobin; Humans; Ophthalmic Solutions; Risk Factors; Tears; Vitrectomy | 2023 |
Tear secretion by Diquafosol suppresses the excitability of trigeminal brainstem nuclear complex neurons by reducing excessive P2Y
Topics: Animals; Brain Stem; Dry Eye Syndromes; Male; Neurons; Rats; Tears; Trigeminal Ganglion | 2023 |
Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Matrix Metalloproteinase 9; Uracil Nucleotides | 2023 |
Effect of 3% Diquafosol Sodium on Dry Eye After Femtosecond Laser-Assisted In Situ Keratomileusis and Small Incision Lenticule Extraction Surgery in High-Myopic Eyes.
Topics: Corneal Stroma; Dry Eye Syndromes; Humans; Hyaluronic Acid; Keratomileusis, Laser In Situ; Lasers, Excimer; Myopia; Ophthalmic Solutions | 2023 |
Effect of Diquafosol on Hyperosmotic Stress-induced Tumor Necrosis Factor-α and Interleukin-6 Expression in Human Corneal Epithelial Cells.
Topics: Blotting, Western; Cells, Cultured; Dry Eye Syndromes; Epithelium, Corneal; Gene Expression Regulation; Humans; Interleukin-6; Ophthalmic Solutions; Polyphosphates; RNA; Signal Transduction; Tears; Tumor Necrosis Factor-alpha; Uracil Nucleotides | 2020 |
Diquafosol tetrasodium elicits total cholesterol release from rabbit meibomian gland cells via P2Y
Topics: Animals; Cells, Cultured; Cholesterol; Dry Eye Syndromes; Meibomian Glands; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Rabbits; Receptors, Purinergic P2Y2; RNA, Messenger; Tears; Uracil Nucleotides | 2021 |
Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
Topics: Activities of Daily Living; Computer Terminals; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Quality of Life; Reading; Staining and Labeling; Surveys and Questionnaires; Tears; Tomography, Optical Coherence; Treatment Outcome; Uracil Nucleotides | 2017 |
Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Histocytochemistry; Hyaluronic Acid; Mice; Ophthalmic Solutions; Peptides; Polyphosphates; Treatment Outcome; Uracil Nucleotides | 2017 |
Long-Term Topical Diquafosol Tetrasodium Treatment of Dry Eye Disease Caused by Chronic Graft-Versus-Host Disease: A Retrospective Study.
Topics: Adult; Aged; Conjunctiva; Cornea; Dry Eye Syndromes; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Mucins; Ophthalmic Solutions; Polyphosphates; Retrospective Studies; Tears; Uracil Nucleotides | 2018 |
The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice.
Topics: Animals; Copper; Disease Models, Animal; Dose-Response Relationship, Drug; Dry Eye Syndromes; Immunohistochemistry; Keratins; Male; Meibomian Glands; Mice; Mice, Inbred C57BL; Mice, Knockout; Ophthalmic Solutions; Polyphosphates; Superoxide Dismutase; Tears; Uracil Nucleotides; Zinc | 2018 |
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides | 2018 |
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
Topics: Adult; Aged; Aged, 80 and over; Blinking; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Retrospective Studies; Surveys and Questionnaires; Tears; Uracil Nucleotides; Young Adult | 2018 |
Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Topics: Administration, Topical; Alanine; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Epithelium, Corneal; Female; Inflammation; Mice; Mice, Inbred C57BL; Mucins; Ophthalmic Solutions; Polyphosphates; Quinolones; Uracil Nucleotides | 2018 |
Diquafosol Sodium Inhibits Apoptosis and Inflammation of Corneal Epithelial Cells Via Activation of Erk1/2 and RSK: In Vitro and In Vivo Dry Eye Model.
Topics: Animals; Apoptosis; Blotting, Western; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Epithelium, Corneal; Female; Inflammation; Keratitis; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ophthalmic Solutions; Phosphorylation; Polyphosphates; Purinergic P2Y Receptor Agonists; Rats; Rats, Wistar; Reactive Oxygen Species; Ribosomal Protein S6 Kinases, 90-kDa; Uracil Nucleotides | 2018 |
Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Topics: Adult; Aged; Cornea; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Oxidants, Photochemical; Ozone; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2019 |
Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.
Topics: Aged; Conjunctiva; Cornea; Dry Eye Syndromes; Female; Fluorescein; Fluorometry; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Tears; Tomography, Optical Coherence; Treatment Outcome; Uracil Nucleotides | 2013 |
Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis.
Topics: Adult; Dry Eye Syndromes; Female; Humans; Keratomileusis, Laser In Situ; Male; Middle Aged; Mucins; Ophthalmic Solutions; Polyphosphates; Postoperative Complications; Prognosis; Prospective Studies; Purinergic P2Y Receptor Agonists; Surveys and Questionnaires; Tears; Uracil Nucleotides; Visual Acuity | 2014 |
Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study.
Topics: Conjunctiva; Cornea; Dry Eye Syndromes; Female; Humans; Japan; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Treatment Outcome; Uracil Nucleotides | 2014 |
Intraocular Scattering after Instillation of Diquafosol Ophthalmic Solution.
Topics: Administration, Topical; Adult; Blinking; Dry Eye Syndromes; Female; Healthy Volunteers; Humans; Light; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Scattering, Radiation; Tears; Uracil Nucleotides; Young Adult | 2015 |
Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Topics: Administration, Topical; Aged; Alanine; Drug Therapy, Combination; Dry Eye Syndromes; Enzyme Inhibitors; Female; Fluorescein; Fluorescent Dyes; Follow-Up Studies; Graft vs Host Disease; Humans; Middle Aged; Ophthalmic Solutions; Pemphigoid, Benign Mucous Membrane; Polyphosphates; Purinergic P2Y Receptor Agonists; Quinolones; Treatment Outcome; Uracil Nucleotides; Visual Acuity | 2015 |
Prominent Decrease of Tear Meniscus Height With Contact Lens Wear and Efficacy of Eye Drop Instillation.
Topics: Adult; Contact Lenses, Hydrophilic; Dry Eye Syndromes; Female; Humans; Male; Ophthalmic Solutions; Polyphosphates; Tears; Tomography, Optical Coherence; Uracil Nucleotides | 2015 |
Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Uracil Nucleotides | 2015 |
Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
Topics: Aged; Drug Administration Schedule; Dry Eye Syndromes; Female; Humans; Lubricant Eye Drops; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Sjogren's Syndrome; Tears; Uracil Nucleotides | 2015 |
Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
Topics: Adult; Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Dry Eye Syndromes; Eye Proteins; Female; Humans; Immunoglobulin A, Secretory; Lactoferrin; Lipocalin 1; Middle Aged; Muramidase; N-Acetylneuraminic Acid; Ophthalmic Solutions; Osmolar Concentration; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Uracil Nucleotides; Young Adult | 2015 |
Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome.
Topics: Dry Eye Syndromes; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Treatment Outcome; Uracil Nucleotides | 2016 |
Evaluation of Tear Meniscus Dynamics Using Anterior Segment Swept-Source Optical Coherence Tomography After Topical Solution Instillation for Dry Eye.
Topics: Administration, Topical; Adult; Alanine; Anterior Eye Segment; Cross-Sectional Studies; Dry Eye Syndromes; Female; Humans; Hyaluronic Acid; Male; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Quinolones; Tears; Tomography, Optical Coherence; Uracil Nucleotides | 2016 |
Diquafosol for Soft Contact Lens Dryness: Clinical Evaluation and Tear Analysis.
Topics: Adult; Chromatography, High Pressure Liquid; Contact Lenses, Hydrophilic; Cornea; Dry Eye Syndromes; Eye Proteins; Female; Fluorophotometry; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides; Young Adult | 2016 |
Diquafosol Ophthalmic Solution Increases Pre- and Postlens Tear Film During Contact Lens Wear in Rabbit Eyes.
Topics: Animals; Contact Lenses, Hydrophilic; Cornea; Disease Models, Animal; Dry Eye Syndromes; Ophthalmic Solutions; Polyphosphates; Rabbits; Tears; Tomography, Optical Coherence; Uracil Nucleotides | 2017 |
The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
Topics: Adult; Aged; Dry Eye Syndromes; Female; Humans; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Retrospective Studies; Sjogren's Syndrome; Uracil Nucleotides | 2016 |
Influence of Ophthalmic Solutions on Tear Components.
Topics: Dry Eye Syndromes; Eye Proteins; Humans; Mucins; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Sodium Chloride; Tears; Uracil Nucleotides | 2016 |
A Clinic-based Survey of Clinical Characteristics and Practice Pattern of Dry Eye in Japan.
Topics: Aged; Alanine; Cross-Sectional Studies; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Female; Humans; Hyaluronic Acid; Japan; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Practice Patterns, Physicians'; Prevalence; Quinolones; Symptom Assessment; Treatment Outcome; Uracil Nucleotides | 2017 |
Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery.
Topics: Aberrometry; Administration, Ophthalmic; Aged; Corneal Wavefront Aberration; Dry Eye Syndromes; Female; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Ophthalmic Solutions; Perioperative Care; Phacoemulsification; Polyphosphates; Purinergic P2Y Receptor Agonists; Retrospective Studies; Tears; Uracil Nucleotides | 2017 |
Emerging treatments for dry eye: some like it hot, while others may prefer a good stimulation.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Hyperthermia, Induced; Immunosuppressive Agents; Massage; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2013 |
INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.
Topics: Animals; Desiccation; Dose-Response Relationship, Drug; Dry Eye Syndromes; Epithelium, Corneal; Male; Mucins; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Rabbits; Staining and Labeling; Uracil Nucleotides | 2002 |
[A molecular marker for dry eye].
Topics: Animals; Biomarkers; Dinucleoside Phosphates; Disease Models, Animal; Dry Eye Syndromes; Humans; Intraocular Pressure; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2007 |
Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
Topics: Animals; Biological Transport; Cornea; Dry Eye Syndromes; Fluorescein; Fluorophotometry; Goblet Cells; Male; Membrane Glycoproteins; Ophthalmic Solutions; Permeability; Polyphosphates; Purinergic P2 Receptor Agonists; Rats; Rats, Sprague-Dawley; Tears; Uracil Nucleotides | 2001 |